Published in Future Med Chem on May 01, 2009
Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J Med Chem (2011) 1.36
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro (2010) 1.21
Broad action of Hsp90 as a host chaperone required for viral replication. Biochim Biophys Acta (2011) 1.13
Development of a Grp94 inhibitor. J Am Chem Soc (2012) 1.06
A systematic protocol for the characterization of Hsp90 modulators. Bioorg Med Chem (2010) 1.04
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem (2009) 1.02
3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med Chem Lett (2012) 1.01
Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach? Pharmacol Rev (2012) 0.99
Approaches for defining the Hsp90-dependent proteome. Biochim Biophys Acta (2011) 0.95
Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. J Org Chem (2013) 0.91
Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem (2011) 0.91
Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorg Med Chem (2014) 0.90
Barcoding heat shock proteins to human diseases: looking beyond the heat shock response. Dis Model Mech (2014) 0.90
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 0.89
Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther (2013) 0.87
Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J Med Chem (2012) 0.86
Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. Int J Oncol (2013) 0.85
Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm (2014) 0.84
Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett (2011) 0.83
Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chem Biol (2014) 0.83
Molecular chaperone Hsp90 is a therapeutic target for noroviruses. J Virol (2015) 0.81
Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy. Expert Rev Proteomics (2010) 0.81
Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors. ACS Med Chem Lett (2014) 0.80
Development of Noviomimetics as C-Terminal Hsp90 Inhibitors. ACS Med Chem Lett (2015) 0.80
Heat shock protein 90 in Alzheimer's disease. Biomed Res Int (2014) 0.79
Impaired surface expression and conductance of the KCNQ4 channel lead to sensorineural hearing loss. J Cell Mol Med (2013) 0.79
Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α. Strahlenther Onkol (2012) 0.79
Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail. ACS Med Chem Lett (2016) 0.78
Gα12 structural determinants of Hsp90 interaction are necessary for serum response element-mediated transcriptional activation. Mol Pharmacol (2014) 0.77
Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy. Curr Diab Rep (2016) 0.75
Heat shock response and insulin-associated neurodegeneration. Trends Pharmacol Sci (2011) 0.75
Promoting Neuronal Tolerance of Diabetic Stress: Modulating Molecular Chaperones. Int Rev Neurobiol (2016) 0.75
X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response. Oncotarget (2016) 0.75
Response of heat shock protein genes of the oriental fruit moth under diapause and thermal stress reveals multiple patterns dependent on the nature of stress exposure. Cell Stress Chaperones (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 21.65
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Multiple sclerosis. N Engl J Med (2000) 12.69
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Protein aggregation and neurodegenerative disease. Nat Med (2004) 9.51
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) (2003) 8.04
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
Amyotrophic lateral sclerosis. N Engl J Med (2001) 7.37
An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature (1997) 7.06
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A (1994) 6.74
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol (2001) 6.10
Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu Rev Biochem (2001) 5.74
Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 5.73
The structure of the tetratricopeptide repeats of protein phosphatase 5: implications for TPR-mediated protein-protein interactions. EMBO J (1998) 5.61
Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell (1998) 5.52
Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature (2006) 5.42
Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci (2005) 5.00
Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol (1999) 4.98
GrpE-like regulation of the hsc70 chaperone by the anti-apoptotic protein BAG-1. EMBO J (1997) 4.68
Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell (2003) 4.46
GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci (2000) 4.20
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem (1999) 4.02
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci (2007) 3.74
Molecular chaperones as HSF1-specific transcriptional repressors. Genes Dev (1998) 3.72
The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther (1998) 3.66
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 3.42
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J (2008) 3.33
Structure of a Bag/Hsc70 complex: convergent functional evolution of Hsp70 nucleotide exchange factors. Science (2001) 3.27
Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3.25
Genetic suppression of polyglutamine toxicity in Drosophila. Science (2000) 3.23
The human cytosolic molecular chaperones hsp90, hsp70 (hsc70) and hdj-1 have distinct roles in recognition of a non-native protein and protein refolding. EMBO J (1996) 3.23
CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep (2001) 3.19
17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med (2005) 3.19
Hsp90: chaperoning signal transduction. J Cell Physiol (2001) 3.13
The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J (2000) 3.00
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A (1996) 2.90
Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell (2003) 2.83
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
RNA-mediated response to heat shock in mammalian cells. Nature (2006) 2.79
17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther (2003) 2.74
Heat shock protein 90. Curr Opin Oncol (2003) 2.73
In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone. Proc Natl Acad Sci U S A (1997) 2.71
Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J Biol Chem (1998) 2.63
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med (2004) 2.59
The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. Mol Biol Cell (2003) 2.56
Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res (2006) 2.55
HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther (2002) 2.53
Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol (2004) 2.50
Huntington's disease: from pathology and genetics to potential therapies. Biochem J (2008) 2.41
Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol (2008) 2.41
Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A (2003) 2.32
Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl) (2004) 2.32
Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet (2001) 2.29
Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett (2004) 2.26
Heat shock proteins as emerging therapeutic targets. Br J Pharmacol (2005) 2.25
Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett (2007) 2.21
The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol (2007) 2.19
Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell (2004) 2.19
The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics (2005) 2.17
Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer (1992) 2.12
X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain (1989) 2.10
Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst (2000) 2.09
Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med (2004) 2.06
Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem (1998) 2.02
Multiple layers of regulation of human heat shock transcription factor 1. Mol Cell Biol (1995) 2.00
Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res (2009) 1.96
Molecular chaperones--cellular machines for protein folding. Angew Chem Int Ed Engl (2002) 1.95
Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin. J Biol Chem (1997) 1.94
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol (1998) 1.93
Development and application of Hsp90 inhibitors. Drug Discov Today (2007) 1.91
Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperones (1998) 1.91
Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure (2005) 1.91
The assembly of progesterone receptor-hsp90 complexes using purified proteins. J Biol Chem (1998) 1.90
The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J Biol Chem (1996) 1.90
Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem (2006) 1.86
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
Pharmacological prevention of Parkinson disease in Drosophila. Nat Med (2002) 1.84
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 1.84
Heat-induced chaperone activity of HSP90. J Biol Chem (1996) 1.80
Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets (2003) 1.80
Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron (2002) 1.78
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A (2007) 1.77
HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol (1998) 1.76
Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. J Biol Chem (2001) 1.75
Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. J Biol Chem (1996) 1.68
Interaction between heat shock factor and hsp70 is insufficient to suppress induction of DNA-binding activity in vivo. Mol Cell Biol (1994) 1.68
The Hsp90 family of proteins in Arabidopsis thaliana. Cell Stress Chaperones (2001) 1.67
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett (2004) 1.67
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
Intramolecular Diels-Alder and tandem intramolecular Diels-Alder/1,3-dipolar cycloaddition reactions of 1,3,4-oxadiazoles. J Am Chem Soc (2002) 2.18
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 1.84
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc (2006) 1.75
Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc (2005) 1.71
Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem (2008) 1.63
Intramolecular diels-alder/1,3-dipolar cycloaddition cascade of 1,3,4-oxadiazoles. J Am Chem Soc (2006) 1.63
A new approach for enhancing differential selectivity of drugs to cancer cells. ACS Chem Biol (2006) 1.62
Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol (2012) 1.59
Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets (2007) 1.51
The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem (2008) 1.49
KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol (2009) 1.43
Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J Med Chem (2011) 1.36
Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Org Lett (2006) 1.33
E. coli MEP synthase: steady-state kinetic analysis and substrate binding. Biochemistry (2002) 1.32
A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett (2007) 1.27
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro (2010) 1.21
Hsp90 as a target for drug development. ChemMedChem (2006) 1.20
Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol (2011) 1.19
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer (2011) 1.17
Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biol Reprod (2008) 1.13
Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays. Comb Chem High Throughput Screen (2013) 1.12
High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorg Med Chem (2007) 1.11
Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity. ACS Med Chem Lett (2010) 1.10
Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org Lett (2005) 1.09
Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org Lett (2004) 1.08
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07
Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. J Biol Chem (2013) 1.07
Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J Mol Biol (2009) 1.06
Development of a Grp94 inhibitor. J Am Chem Soc (2012) 1.06
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorg Med Chem (2008) 1.05
A systematic protocol for the characterization of Hsp90 modulators. Bioorg Med Chem (2010) 1.04
Hsp90 modulation for the treatment of Alzheimer's disease. Adv Pharmacol (2012) 1.03
Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem (2006) 1.03
Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90. J Org Chem (2006) 1.03
High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett (2006) 1.02
Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorg Med Chem Lett (2010) 1.02
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem (2009) 1.02
A library of noviosylated coumarin analogues. J Org Chem (2007) 1.01
3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med Chem Lett (2012) 1.01
Uptake, distribution and diffusivity of reactive fluorophores in cells: implications toward target identification. Mol Pharm (2010) 1.00
Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorg Med Chem (2005) 0.99
Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorg Med Chem (2008) 0.96
C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. J Proteome Res (2012) 0.96
Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate (2010) 0.96
Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod (2011) 0.96
Hsp90 inhibition: elimination of shock and stress. Bioorg Med Chem Lett (2010) 0.95
Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorg Med Chem Lett (2006) 0.95
Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. J Biol Chem (2012) 0.95
Synthesis and evaluation of electron-rich curcumin analogues. Bioorg Med Chem (2008) 0.94
Syntheses of photolabile novobiocin analogues. Bioorg Med Chem Lett (2004) 0.94
Biotinylated geldanamycin. J Org Chem (2004) 0.92
Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. J Med Chem (2012) 0.92
Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. J Org Chem (2013) 0.91
Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem (2011) 0.91
A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases. Assay Drug Dev Technol (2010) 0.90
Synthesis and evaluation of derrubone and select analogues. J Org Chem (2007) 0.89
The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Mol Pharm (2012) 0.89
Derrubone, an inhibitor of the Hsp90 protein folding machinery. J Nat Prod (2007) 0.88
Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther (2013) 0.87
Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues. Bioorg Med Chem Lett (2010) 0.86
3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. ACS Med Chem Lett (2012) 0.86
Synthesis of mono- and dihydroxylated furanoses, pyranoses, and an oxepanose for the preparation of natural product analogue libraries. J Org Chem (2005) 0.86
Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J Med Chem (2012) 0.86
Novobiocin analogues with second-generation noviose surrogates. Bioorg Med Chem Lett (2012) 0.85
Synthesis of (-)-noviose from 2,3-O-isopropylidene-D-erythronolactol. J Org Chem (2004) 0.84
Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett (2009) 0.84
Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Med Chem (2014) 0.84
Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. J Org Chem (2009) 0.83
Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett (2011) 0.83
Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chem Biol (2014) 0.83
Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. Ann Surg Oncol (2011) 0.82
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro (2012) 0.81
Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model (2014) 0.81
The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone. Bioorg Med Chem (2009) 0.79
Synthesis of cruentaren A. Org Lett (2012) 0.79
KU-32, a novel drug for diabetic neuropathy, is safe for human islets and improves in vitro insulin secretion and viability. Exp Diabetes Res (2012) 0.78
Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells. Bioorg Med Chem Lett (2007) 0.78
Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol (2013) 0.78
Hydrating for resistance to radicicol. ACS Chem Biol (2009) 0.77
Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorg Med Chem Lett (2009) 0.77
Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery. ACS Chem Biol (2014) 0.76
Synthesis of a versatile metacyclophane macrolactam. Tetrahedron Lett (2008) 0.75
Heat shock response and insulin-associated neurodegeneration. Trends Pharmacol Sci (2011) 0.75
Monoenomycin: A Simplified Trienomycin A Analogue that Manifests Anticancer Activity. ACS Med Chem Lett (2011) 0.75
Inhibition and function of heat shock proteins 70 and 90. Curr Top Med Chem (2009) 0.75
A versatile approach toward the ansamycin antibiotics. Org Lett (2006) 0.75
Recent advances in medicinal chemistry. Bioorg Med Chem Lett (2011) 0.75